Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 WuXi AppTec Opens Bio-Facility in China | Contract Pharma

What are you searching for?

Sign in
Breaking News

WuXi AppTec Opens Bio-Facility in China

Will use 100% disposable equipment for biologics manufacturing

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

WuXi AppTec has opened its cGMP biologics manufacturing facility in Wuxi, China and hosted its first Global Monoclonal Antibody Summit in conjunction with the opening. The company has invested in growing its capabilities and capacity in biologics in the past few years. The manufacturing facility in Wuxi is the first in China to meet GMP standards of the U.S., EU and China, and uses 100% disposable equipment for biologics drug substance manufacturing.

“The establishment of this cGMP biologics facility has greatly improved WuXi’s services in biologics manufacturing and further showcases our commitment to global clients,” said Dr. Ge Li, chairman and chief executive officer of WuXi AppTec. “WuXi is determined to provide world-class services for anyone conducting research in biologics discovery, development and manufacturing including multinational and Chinese pharmaceutical and biotech companies.”

The company recently announced contracts with Open Monoclonal Technology to use OmniRat to develop human antibodies, a contract with TaiMed Biologics to produce the HIV compound ibalizumab for global Phase II and III trials, and a joint venture with MedImmune to develop MEDI5117, an IL-6 inhibitor for rheumatoid arthritis and autoimmune disorders in China.

Dr. Martin Mackay, president of R&D at AstraZeneca, attended the opening ceremony and stressed that the joint venture with WuXi will help both companies bring benefit to patients. He remarked, “No single company has all the solutions to the healthcare challenges of today. That’s why collaborations such as our joint venture with WuXi AppTec are so important. Our mutual ambition is to greatly increase the number of people who ultimately benefit from our medicines.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters